Effect of single and multiple doses of 0.2% brimonidine tartrate in the glaucomatous Beagle
- PMID: 12445295
- DOI: 10.1046/j.1463-5224.2002.00222.x
Effect of single and multiple doses of 0.2% brimonidine tartrate in the glaucomatous Beagle
Abstract
The objective of this study was to evaluate the changes in intraocular pressure (IOP) in glaucomatous dogs after instillations of 0.2% brimonidine once, twice and three times daily in single day studies, and after twice and three times daily for 4 days in multiple dose studies. We studied eight Beagles with inherited primary open angle glaucoma. Applanation tonometry (IOP), pupil size (PS) and heart rate (HR) measurements were obtained at 8 am, 10 am, 1 pm, 3 pm and 5 pm. The studies were divided into: eight glaucoma dogs and five of the eight dogs that demonstrated greater response to 0.2% brimonidine. Single-dose drug studies are divided into placebo (0.5% methylcellulose), 0.2% brimonidine administered once daily (8 am); twice daily (8 am and noon); and three times daily (8 am, noon and 5 pm). The 5-day multiple-dose studies included: day 1, no drug; and 4 days, 0.2% brimonidine instillations either twice daily (8 am and 2 pm) or three times daily (8 am, 2 pm and 9 pm). Statistical comparisons between drug groups included control (nondrug) and treated (placebo/0.2% brimonidine) eyes for both single- and multiple-dose studies. The mean +/- SEM diurnal decrease in IOP in the eight glaucomatous Beagles for the control and placebo eyes were 3.4 +/- 4.7 and 5.4 +/- 2.8 mmHg, respectively. The mean +/- SEM diurnal decrease in IOP after 0.2% brimonidine once, twice and three times daily was 6.4 +/- 3.5, 8.0 +/- 6.1 and 9.8 +/- 8.1 mmHg, respectively; this trend was not significant statistically. Significant miosis occurred starting 2 h postinstillations, and the resultant mean +/- SD pupil size was 2.7 +/- 0.3 mm. A significant decrease in heart rate also occurred (12%). In the five most responsive dogs the changes in PS and HR during these studies were similar to the larger group, but significant decreases in IOP occurred at most measurement times. In the multiple-dose study with 0.2% brimonidine twice daily the mean +/- SEM decrease in IOP for day 1 to day 4 was 5.0 +/- 1.3, 5.7 +/- 1.3, 1.4 +/- 3.3 and 4.9 +/- 1.3 mmHg, respectively. When 0.2% brimonidine was instilled three times daily the mean +/- SEM diurnal IOP decrease was from day 1 to day 4 and was 0.75 +/- 1.3, 2.4 +/- 1.5, 1.2 +/- 2.7 and 1.4 +/- 1.8 mmHg, respectively. The mean change in pupil diameter was 1.3 +/- 0.5 mm. Decrease in HR averaged 22%. In the same single-dose studies with the five most responsive dogs, PS and HR were similar, but the decreases in IOP were significant at more measurement intervals. We conclude that 0.2% brimonidine produces a decrease in IOP in dogs, a statistically significant miosis, and a reduced heart rate (12-22%). However, because of the limited drug-induced ocular hypotension, brimonidine should be combined with other drugs when used for the glaucomas in the dog.
Similar articles
-
Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle.Vet Ophthalmol. 2001 Dec;4(4):283-8. doi: 10.1046/j.1463-5216.2001.00201.x. Vet Ophthalmol. 2001. PMID: 11906665 Clinical Trial.
-
Changes in intraocular pressure associated with topical dorzolamide and oral methazolamide in glaucomatous dogs.Vet Ophthalmol. 2001 Mar;4(1):61-7. doi: 10.1046/j.1463-5224.2001.00141.x. Vet Ophthalmol. 2001. PMID: 11397321
-
Effect of different dose schedules of 0.15% unoprostone isopropyl on intraocular pressure and pupil size in the glaucomatous beagle.J Ocul Pharmacol Ther. 2004 Oct;20(5):411-20. doi: 10.1089/jop.2004.20.411. J Ocul Pharmacol Ther. 2004. PMID: 15650516
-
Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.Surv Ophthalmol. 1996 Nov;41 Suppl 1:S19-26. doi: 10.1016/s0039-6257(96)82028-5. Surv Ophthalmol. 1996. PMID: 8970246 Review.
-
Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.Drugs Aging. 2006;23(9):753-61. doi: 10.2165/00002512-200623090-00005. Drugs Aging. 2006. PMID: 17020399 Review.
Cited by
-
Looking into the future: Gene and cell therapies for glaucoma.Vet Ophthalmol. 2021 Mar;24 Suppl 1(Suppl 1):16-33. doi: 10.1111/vop.12858. Epub 2021 Jan 7. Vet Ophthalmol. 2021. PMID: 33411993 Free PMC article. Review.
-
Antiemetic effect of oral maropitant treatment before the administration of brimonidine ophthalmic solution in healthy cats.J Feline Med Surg. 2020 Jun;22(6):557-563. doi: 10.1177/1098612X19862687. Epub 2019 Jul 17. J Feline Med Surg. 2020. PMID: 31313970 Free PMC article.
-
Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes.Equine Vet J. 2017 Nov;49(6):810-814. doi: 10.1111/evj.12695. Epub 2017 Jun 5. Equine Vet J. 2017. PMID: 28470857 Free PMC article.
-
Presumed neuroprotective therapies prescribed by veterinary ophthalmologists for canine degenerative retinal and optic nerve diseases.Vet Ophthalmol. 2021 May;24(3):229-239. doi: 10.1111/vop.12878. Epub 2021 Mar 7. Vet Ophthalmol. 2021. PMID: 33682296 Free PMC article.
-
Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma.Int J Mol Sci. 2022 Jul 22;23(15):8068. doi: 10.3390/ijms23158068. Int J Mol Sci. 2022. PMID: 35897642 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases